Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations
Francesco Panzuto(Sapienza University of Rome), Davide Campana(University of Bologna), Antongiulio Faggiano(European Neuroendocrine Tumor Society), Salvatore Tafuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ilaria Maggio(University of Bologna), Bruno Annibale(Azienda Ospedaliera Sant'Andrea), Sara Pusceddu(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Rinzivillo(Sapienza University of Rome), Elsa Iannicelli(Azienda Ospedaliera Sant'Andrea), Nicole Brighi(London Cancer), Natalie Prinzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonella Di Sarno(Molecular Oncology (United States)), Lisa Manuzzi(University of Bologna), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Daniela Femia(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(University of Milan)
Cited by 27
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Persistence of Increased Cardiovascular Risk in Patients with Cushing’s Disease after Five Years of Successful Cure
|The Journal of Clinical Endocrinology & Metabolism|1999|417